Assertio Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 03, 2023 at 09:04 pm
Share
Assertio Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 40.99 million compared to USD 35.13 million a year ago. Net income was USD 8.47 million compared to USD 7.83 million a year ago. Basic earnings per share from continuing operations was USD 0.15 compared to USD 0.17 a year ago. Diluted earnings per share from continuing operations was USD 0.13 compared to USD 0.16 a year ago.
For the six months, revenue was USD 83.46 million compared to USD 71.67 million a year ago. Net income was USD 4.99 million compared to USD 16.9 million a year ago. Basic earnings per share from continuing operations was USD 0.09 compared to USD 0.37 a year ago. Diluted earnings per share from continuing operations was USD 0.09 compared to USD 0.36 a year ago.
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).